LEGEND STRAT (01355) intends to acquire 100% of the issued share capital of Ohno Hong Kong.

LEGEND STRAT (01355) announced that on December 23, 2025, the Company's wholly-owned subsidiary Jia Yi Environmental Global, as the buyer, entered into a sale and purchase agreement with Ms. Zheng Tong, the seller, under which the seller conditionally agreed to sell and the buyer conditionally agreed to purchase the sale shares (representing 100% of the issued share capital of the target company Aono Hong Kong) and the sale loan for a total consideration of HKD 22 million. Upon completion, the target company will become an indirect wholly-owned subsidiary of the Company, and the Company will hold a 37.5% equity interest in Bei Sheng Biology. The financial performance, assets, and liabilities of Bei Sheng Biology Group will be accounted for in the Company's financial statements using the equity method. Bei Sheng Biology is a synthetic biology infrastructure supplier focused on strain design and fermentation process development, providing higher quality, more convenient, and lower cost technology services and related products to synthetic biology companies, biopharmaceutical companies, and traditional fermentation companies looking to upgrade their industries using synthetic biology technology. The Group believes that the development of proprietary rights and technology related to the healthcare and beauty business is key to gaining a competitive advantage. The Group's current focus areas for research and development include: - Type III collagen-hyaluronic acid "double protein" hyaluronic acid injection, mainly using hyaluronic acid permeation enhancement technology, with recombinant type III collagen+acetylated hyaluronic acid (AcHA) as composite components to improve transdermal absorption efficiency, achieving instant filling and long-term regeneration; - Hydroxyapatite/collagen composite filler, targeting the large market for temple fillers; - Photo-activated collagen repair essence, aiming to develop essences containing thermosensitive/photosensitive liposomes that release collagen peptide under specific wavelength irradiation for precise repair; and - Mesenchymal stem cell exosome targeting anti-aging therapy, targeting the development of freeze-dried exosome microspheres for targeted release and long-term repair. During the development process, the Group was presented with an opportunity to acquire a synthetic biology infrastructure supplier, Bei Sheng Jinyu Bio-Technology, which focuses on strain design and fermentation process development. Bei Sheng Biology has established a comprehensive closed-loop synthetic biology infrastructure encompassing design software, vectors and strain standard architecture, DNA and strain production platforms, data generation, as well as R&D and production of process-related reagents and equipment. Moreover, Bei Sheng Biology also has complete DNA synthesis capabilities, core molecular fermentation R&D and production capabilities, and protein, small molecule, and composite product fermentation R&D and production capabilities from small to medium scale. The Group believes that acquiring equity in Bei Sheng Biology through the acquisition will ensure access to Bei Sheng Biology's services, improve the efficiency of its own R&D projects, reduce R&D costs, and accelerate the commercialization of R&D results. After reasonable inquiry and full consideration by the directors, all existing shareholders and management of Bei Sheng Biology are independent third parties. Following the completion of the acquisition, the Group will have the right to nominate and replace up to 2 directors on the current board of directors of Bei Sheng Biology (comprising 5 members).